Method for detecting related substances of ezetimibe and atorvastatin calcium compound preparation
By using pentafluorophenyl chromatography column and gradient elution technology in the erzemaibu atorvastatin calcium compound preparation, the problem of separation of degraded impurities and main peaks was solved, and the effective separation of process impurities and degraded impurities was achieved, satisfying the satisfaction of The quality control requirements are improved and the quality control accuracy of the preparation is improved.
Patent Information
- Application Number
- CN202310500600.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-06
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively separate the degraded impurities and main peaks in the compound preparation of erzemaibu atorvastatin, and the separation effect between multiple known process impurities and degraded impurities is poor, resulting in difficulty in quality control.
A pentafluorophenyl chromatography column was used, and the gradient elution was performed using ammonium acetate buffer pH 4.8-5.2, acetonitrile and methanol as mobile phases. Combined with appropriate column gentle flow velocity conditions, effective separation between degraded impurities and the main peak was achieved.
This method can effectively separate degraded impurities and main peaks, and meet the separation requirements between multiple known process impurities and degraded impurities, ensure the quality control of ezemaibu atorvastatin calcium compound preparation, and improve the accuracy of quality control and reliability.
Smart Images

Figure CN118914378A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of drug analysis, and in particular to a method for detecting related substances in an ezetimibe and atorvastatin calcium compound preparation. Background Art
[0002] Ezetimibe atorvastatin calcium tablets were developed by Schering-Plough (later acquired by Merck) and were first approved by the FDA in 2013 under the trade name Other countries where this drug has been approved for marketing include Italy, France, Spain, Japan, etc. This drug has not yet been approved in China. So far, none of the pharmacopoeias of various countries have included the detection methods for the relevant substances of this drug. Since atorvastatin has poor stability and is a typical drug with many impurities, and ezetimibe also has poor stability, on the one hand, strictly controlling the quality of the compound preparation composed of these two active ingredients is very important for its safety and effectiveness in clinical use. On the other hand, it is also very difficult to develop a quality control method suitable for this compound preparation. Summary of the invention
[0003] The purpose of the present invention is to provide a method for detecting related substances of ezetimibe and atorvastatin calcium compound preparations, which can achieve effective separation between degradation impurities and main peaks, and the separation between multiple known process impurities and degradation impurities can also meet the quality control requirements, which is of great significance to the quality control of ezetimibe and atorvastatin calcium compound preparations.
[0004] The technical solution adopted by the present invention is as follows:
[0005] A method for detecting related substances in an ezetimibe atorvastatin calcium compound preparation adopts a pentafluorophenyl chromatographic column, uses an ammonium acetate buffer solution with a pH value of 4.8-5.2 as a mobile phase A, acetonitrile as a mobile phase B, and methanol as a mobile phase C, and performs gradient elution to detect related substances in the ezetimibe atorvastatin calcium compound preparation.
[0006] In a preferred embodiment of the present invention, the concentration of ammonium acetate in mobile phase A is 3.8-4.0 g / L, and glacial acetic acid is used to adjust the pH.
[0007] In a preferred embodiment of the present invention, the concentration of ammonium acetate in mobile phase A is 3.9 g / L, and the pH is adjusted to 5.0 with glacial acetic acid.
[0008] In a preferred embodiment of the present invention, the elution procedure is:
[0009] Time min A% B% C% 0 55 25 20 40 47 25 28 60 39 33 28 75 10 62 28 80 10 62 28 80.1 55 25 20 90 55 25 20 .
[0010] In a preferred embodiment of the present invention, the elution procedure is:
[0011] Time min A% B% C% 0 55 25 20 30 49 25 26 40 47 27 26 50 43 31 26 65 13 61 26 70 13 61 26 70.1 55 25 20 75 55 25 20 .
[0012] In a preferred embodiment of the present invention, the detection wavelength is 245-250 nm.
[0013] In a preferred embodiment of the present invention, the detection wavelength is 248 nm.
[0014] In a preferred embodiment of the present invention, the column temperature is 25-35°C; the flow rate is 1-2 ml / min.
[0015] In a preferred embodiment of the present invention, the column temperature is 30°C and the flow rate is 1.5 ml / min.
[0016] Compared with the prior art, the beneficial effects of the present invention are as follows: the detection method of related substances of the ezetimibe atorvastatin calcium compound preparation provided by the present invention can achieve effective separation between degradation impurities and the main peak, and the separation between multiple known process impurities and degradation impurities can meet the quality control requirements, which is of great significance to the quality control of the ezetimibe atorvastatin calcium compound preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 It is the chromatogram in Comparative Example 1;
[0018] Figure 2 It is the chromatogram in Comparative Example 2;
[0019] Figure 3 It is the chromatogram in Comparative Example 3;
[0020] Figure 4 It is the chromatogram in Comparative Example 4;
[0021] Figure 5 It is the chromatogram in Comparative Example 5;
[0022] Figure 6 It is the chromatogram in Comparative Example 6;
[0023] Figure 7 is the chromatogram in Example 1;
[0024] Figure 8 is the chromatogram in Example 2;
[0025] Fig. 9 This is the chromatogram in Example 3. DETAILED DESCRIPTION
[0026] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention.
[0027] It should be noted that the related substances in the preparation are divided into process impurities and degradation impurities. Generally speaking, since the process impurities have been controlled at the API stage and generally do not grow during the preparation process and stability process, the control of the related substances in the preparation mainly focuses on degradation impurities, and there is no need to control the process impurities. Therefore, for the detection method of the related substances in this application, the applicant focuses on the detection of degradation impurities and the interference of process impurities on degradation impurities, and does not pursue the complete separation of process impurities from degradation impurities. The study of process impurities is only to determine the control risk when process impurities exist in the control of degradation impurities.
[0028] It should also be noted that due to the large number of impurities, it is difficult to distinguish the positions of the impurities in the mixed solution. During the investigation, the present invention separately prepared the main component of atorvastatin calcium and the impurity reference solution (containing the main component of atorvastatin calcium and impurities), and the main component of ezetimibe and the impurity reference solution to confirm the method. For the convenience of description, in the present invention, atorvastatin calcium can be described as "ATV", ezetimibe as "EZT", and the ezetimibe atorvastatin calcium compound preparation can be described as "EZT-ATV compound preparation".
[0029] The information of the relevant material samples used in the present invention is shown in Tables 1 and 2.
[0030] Table 1 Information on related substances of Ezetimibe
[0031]
[0032]
[0033]
[0034] Table 2 Information on related substances of atorvastatin
[0035]
[0036]
[0037]
[0038]
[0039] Comparative Example 1
[0040] Atorvastatin calcium impurity mixed solution: Accurately weigh appropriate amounts of ATV impurities Ⅰ / Ⅱ / Ⅲ / Ⅳ / Ⅴ / Ⅵ / Ⅶ / Ⅷ and atorvastatin raw material, and use N,N-dimethylformamide (DMF) to prepare a mixed solution containing about 0.025 mg / ml of atorvastatin and about 0.025 mg / ml of each impurity.
[0041] Solution for localizing the main component of ezetimibe and each impurity: Take appropriate amounts of the ezetimibe raw material, impurity A, impurity B, impurity C, impurity E, impurity F, impurity G, impurity H, SSS enantiomer, RRR enantiomer, RRS enantiomer, SSR enantiomer, and RSR enantiomer reference substances, dissolve them in DMF to prepare a solution containing approximately 0.65 mg / ml of ezetimibe and approximately 0.1 mg / ml of each impurity.
[0042] Chromatographic column: Agilent Zorbax RX-C8 4.6*250 5um; column temperature: 35°C; detection wavelength: 244nm; injection volume: 20μl, flow rate: 1.0ml / min.
[0043] pH 5.0 ammonium acetate buffer: 3.9g / L ammonium acetate solution, adjust pH to 5.0 with glacial acetic acid. (The same below)
[0044] Mobile phase A: acetonitrile-tetrahydrofuran-pH 5.0 ammonium acetate buffer (21:12:67) (volume ratio, the same below);
[0045] Mobile phase B: acetonitrile-tetrahydrofuran-pH 5.0 ammonium acetate buffer (61:12:27); elution program is shown in Table 1.
[0046] Table 3 Elution program
[0047] Time min A% B% 0 100 0 60 100 0 105 20 80 130 0 100 132 0 100 132.1 100 0 140 100 0
[0048] The test results are shown in Table 4 and Figure 1 shown. Figure 1 In the figure, A is the chromatogram of the impurity mixed solution of atorvastatin calcium, and B is the superimposed chromatogram of ezetimibe and each impurity. Figure 1 As shown in the figure, under this chromatographic condition, atorvastatin calcium and its impurities can be effectively separated, but there is a separation risk for each impurity of ezetimibe. Impurity B of ezetimibe may overlap with the main peak of atorvastatin, impurity E / F / SSS isomers / RRR isomers of ezetimibe cannot be separated, three isomers of ezetimibe (RSR / SSR / RRS) overlap with the main peak of ezetimibe, and degradation impurity A and degradation impurity C of ezetimibe may be difficult to separate by baseline.
[0049] Table 4 Summary of active ingredients and impurities
[0050]
[0051] Note: (1) ATV-VIII is an impurity of ATV isomers, and its peak is superimposed on the main peak in the chromatogram. (2) The peak with a retention time of 94.103 in Figure A is an impurity peak resulting from the degradation of ATV-VI.
[0052] Comparative Example 2
[0053] ① ATV impurity mixed solution: Use DMF as a diluent to prepare a mixed solution containing about 0.025 mg / ml of each of Atorvastatin impurities Ⅰ / Ⅱ / Ⅲ / Ⅳ / Ⅴ / Ⅵ / Ⅶ and the main component of atorvastatin.
[0054] ②EZT impurity mixed solution: Using N,N-dimethylformamide as a diluent, prepare a mixed solution containing impurities A / B / C / E / F / G / H and the main component of ezetimibe at a concentration of approximately 0.1 mg / ml each.
[0055] ③ EZT enantiomer mixed solution: Using N,N-dimethylformamide as a diluent, prepare a mixed solution containing about 0.1 mg / ml of each of SSS / RRR / SSR / RRS / RSR and ezetimibe as the main component.
[0056] Chromatographic column: pentafluorophenyl (PFP) column, Waters Viridis CSH PFP, 4.6×150, 5 um; detection wavelength 248 nm; other chromatographic conditions are the same as those in Comparative Example 1.
[0057] The test results are shown in Table 5 and Figure 2 shown. Figure 2 In the figure, A is the chromatogram of the ATV impurity mixed solution, B is the chromatogram of the EZT impurity mixed solution; C is the chromatogram of the EZT enantiomer impurity mixed solution. The Waters ViridisCSH PFP chromatographic column was used in this comparative example, which had no significant advantage over the investigation results of the C8 chromatographic column used in comparative example 1. The 8 components in the ATV impurity mixed solution had a total of 8 peaks, of which the separation degree between peak 3 and peak 4 was 0.75, and baseline separation could not be achieved. The EZT impurity mixed solution had a total of 6 peaks in the 8 components, and there was peak overlap between three components. The separation degree between peak 3 and peak 4 was only 1.15, and the separation effect was poor. The 6 components in the EZT isomer mixed solution had a total of 2 peaks, and the enantiomers may be superimposed on the main peak of ezetimibe.
[0058] Table 5 Investigation results of various impurity mixed solutions
[0059]
[0060] Note: In Table 5, the “ / ” under the separation degree item means that the impurities are not separated and the separation degree cannot be calculated. The same applies below.
[0061] Comparative Example 3
[0062] The detection solution is the same as that of Comparative Example 2.
[0063] Chromatographic column: pentafluorophenyl (PFP) column, Phenomenex kinetex PFP, 4.6*150,5um; column temperature: 30°C; detection wavelength 248nm; injection volume 20μl, flow rate 2.0ml / min.
[0064] Mobile phase A: pH 5.0 ammonium acetate buffer; mobile phase B: acetonitrile; mobile phase C: methanol. The elution program is shown in Table 6.
[0065] Table 6 Elution program
[0066] Time min A% B% C% 0 63 27 10 37 63 27 10 60 40 50 10 70 40 50 10 80 10 80 10 90 10 80 10 90.1 63 27 10 100 63 27 10
[0067] The results of the investigation are shown in Table 7 and Figure 3 shown. Figure 3 In the figure, A is the chromatogram of the ATV impurity mixed solution, B is the chromatogram of the EZT impurity mixed solution; C is the chromatogram of the EZT enantiomer impurity mixed solution. In Table 7, all the peaks in the three solutions were re-integrated in the order of retention time for comprehensive analysis. There is a separation risk between peaks 1, 2, and 7 in the EZT impurity mixed solution and peaks 4, 5, and 6 in the ATV impurity mixed solution; there is a separation risk between peak 4 in the EZT impurity mixed solution and the EZT isomer peak.
[0068] Table 7 Comprehensive analysis results of peak distribution of each impurity mixed solution
[0069]
[0070]
[0071] Comparative Example 4
[0072] API spiked mixed solution: Use 60% DMF solution as diluent to prepare a mixed solution containing about 0.0125 mg / ml of atorvastatin impurities Ⅰ / Ⅱ / Ⅲ / Ⅳ / Ⅴ / Ⅵ / Ⅶ, about 0.005 mg / ml of ezetimibe impurities A / B / C / E / F / G / H and about 0.005 mg / ml of ezetimibe SSS / RRR / SSR / RRS / RSR isomers, about 1 mg / ml of atorvastatin calcium, and about 0.5 mg / ml of ezetimibe.
[0073] Atorvastatin calcium impurity I / J / K / L / M / N / O mixed solution: A 60% DMF solution was used as a diluent to prepare a mixed solution containing about 0.0125 mg / ml of atorvastatin calcium impurities I / J / K / L / M / N / O, wherein impurity K includes two isomers, K1 and K2.
[0074] Chromatographic column: pentafluorophenyl (PFP) column, Phenomenex kinetex PFP, 4.6*250,5um; column temperature: 30°C; detection wavelength 248nm; injection volume 20μl, flow rate 1.5ml / min.
[0075] Mobile phase A: pH 5.0 ammonium acetate buffer; mobile phase B: methanol; mobile phase C: acetonitrile-tetrahydrofuran (7:3). The elution program is shown in Table 8.
[0076] Table 8 Elution program
[0077] Time min A% B% C% 0 65 25 10 45 49 41 10 60 46 44 10 80 16 74 10 85 16 74 10 85.1 65 25 10 90 65 25 10
[0078] The results of the investigation are shown in Table 9 and Figure 4 shown. Figure 4 In the figure, A is the chromatogram of the mixed solution spiked with the API, and B is the chromatogram of the mixed solution of ATV impurities I / J / K / L / M / N / O. The chromatograms of the mixed solution spiked with the API and the mixed solution containing ATV impurities I / J / K / L / M / N / O were processed and the retention time of each peak was analyzed. For the degradation impurities of concern, impurities ATV-K1 and ATV-J, ATV-K2 and ATV-Ⅳ(4), ATV-Ⅵ(6) and ATV-O all had peak overlaps and were difficult to separate.
[0079] Table 9 Comprehensive analysis results of each substance peak in the mixed solution
[0080]
[0081] Comparative Example 5
[0082] A spiked mixed solution of the raw material drug containing major degradation impurities was prepared using 60% DMF (containing 0.2% acetic acid) (containing atorvastatin impurities IV / VI / I / J / K / L / M / N / O each at approximately 0.005 mg / ml, ezetimibe impurities A / B / C each at approximately 0.005 mg / ml, atorvastatin calcium at approximately 1 mg / ml, and ezetimibe at approximately 0.5 mg / ml).
[0083] Chromatographic column: pentafluorophenyl (PFP) column, Phenomenex luna PFP 110A, 4.6×250, 5um; column temperature: 30°C; detection wavelength 248nm; injection volume 20μl, flow rate 1.5ml / min.
[0084] A: pH 5.0 ammonium acetate buffer; B: methanol; C: acetonitrile-tetrahydrofuran (7:3). The elution procedure is shown in Table 10.
[0085] Table 10 Elution program
[0086] Time min A% B% C% 0 56 34 10 50 43 47 10 80 28 62 10 98 10 80 10 110 10 80 10 110.1 56 34 10 120 56 34 10
[0087] The results of the investigation are shown in Table 11 and Figure 5 As shown. This chromatographic condition can finally achieve the separation of most degradation impurities from adjacent peaks, but the degradation impurities ATV-IV and ATV-K cannot be separated. It should be noted that the Atova impurity J is unstable and degraded during the detection process, so the impurity information is not included in the spectrum.
[0088] Table 11 Analysis results of peaks of various substances in mixed solution
[0089]
[0090] Comparative Example 6
[0091] A spiked mixed solution of the raw material drug containing major degradation impurities was prepared using 60% DMF (containing 0.2% acetic acid) (containing atorvastatin impurities IV / VI / I / J / K / L / M / N / O, ezetimibe impurities A / B / C / E / F, ezetimibe SSS / RRR / SSR / RRS / RSR isomer impurities each about 0.005 mg / ml, atorvastatin calcium about 1 mg / ml, and ezetimibe about 0.5 mg / ml).
[0092] Chromatographic column: pentafluorophenyl (PFP) column, ACE Excel 5-C18 PFP; column temperature: 30°C; detection wavelength: 248nm; injection volume: 20μl, flow rate: 1.5ml / min.
[0093] Mobile phase A: pH 5.0 ammonium acetate buffer; mobile phase B: acetonitrile; mobile phase C: methanol-tetrahydrofuran (7:3). The elution program is shown in Table 12.
[0094] Table 12 Elution program
[0095] Time min A% B% C% 0 65 15 20 40 57 23 20 70 48 32 20 100 15 65 20 110 15 65 20 110.1 65 15 20 120 65 15 20
[0096] The results of the investigation are shown in Table 13 and Figure 6 In this chromatographic system, the degradation impurities can be separated from each other, but the resolution between the degradation impurity I and atorvastatin peaks is poor, about 1.49.
[0097] Table 13 Analysis results of each substance peak in the mixed solution
[0098]
[0099]
[0100] Example 1
[0101] A spiked mixed solution of the raw material drug containing major degradation impurities and high-risk process impurities that may interfere with detection was prepared using 60% DMF (containing 0.2% acetic acid) (containing atorvastatin impurities IV / VI / I / J / K / L / M / N / O, ezetimibe impurities A / B / C / E / F / G impurities each about 0.005 mg / ml, atorvastatin calcium about 1 mg / ml, and ezetimibe about 0.5 mg / ml).
[0102] Chromatographic column: pentafluorophenyl (PFP) column, ACE Excel 5-C18 PFP, 4.6×250, 5um; column temperature: 30°C; detection wavelength 248nm; injection volume 20μl, flow rate 1.5ml / min.
[0103] Mobile phase A: pH 5.0 ammonium acetate buffer; mobile phase B: acetonitrile; mobile phase C: methanol. The elution program is shown in Table 17.
[0104] Table 14 Elution program
[0105] Time min A% B% C% 0 55 25 20 40 47 25 28 60 39 33 28 75 10 62 28 80 10 62 28 80.1 55 25 20 90 55 25 20
[0106] The results of the investigation are shown in Table 15 and Figure 7 As shown. Under the chromatographic conditions, each degradation impurity can be separated, and the main degradation impurity I can be separated from the atorvastatin peak, that is, this method is suitable for the determination of related substances in ezetimibe and atorvastatin calcium compound preparations. It should be noted that atorvastatin impurities J and L are unstable and degraded during the detection process, so the spectrum does not contain information on these two impurities.
[0107] Table 15 Analysis results of peaks of various substances in mixed solution
[0108]
[0109]
[0110] Note: (1) The separation between ATV-Ⅳ(4) and ATV-K1 is slightly poor, but still acceptable and can meet the control requirements; (2) The process impurity EZT-G and the degradation impurity EZT-C are difficult to separate, but they are acceptable to meet the control targets.
[0111] Example 2
[0112] A spiked mixed solution of the raw material drug containing major degradation impurities and high-risk process impurities that may interfere with detection was prepared using 60% DMF (containing 0.2% acetic acid) (containing atorvastatin impurities IV / VI / I / K / M / N / O, ezetimibe impurities A / B / C / E / F / G impurities each about 0.005 mg / ml, atorvastatin calcium about 1 mg / ml, and ezetimibe about 0.5 mg / ml).
[0113] Chromatographic column: pentafluorophenyl (PFP) column, ACE Excel 5-C18 PFP, 4.6×250, 5um; column temperature: 30°C; detection wavelength 248nm; injection volume 20μl, flow rate 1.5ml / min.
[0114] Mobile phase A: pH 5.0 ammonium acetate buffer; mobile phase B: acetonitrile; mobile phase C: methanol. The elution program is shown in Table 16.
[0115] Table 16 Elution program
[0116] Time min A% B% C% 0 55 25 20 30 49 25 26 40 47 27 26 50 43 31 26 65 13 61 26 70 13 61 26 70.1 55 25 20 75 55 25 20
[0117] The test results are shown in Table 17 and Figure 8 The chromatographic conditions shortened the analysis time (the method running time was 75 min) on the basis of meeting the main goal of separation of each impurity, and further improved the separation effect of process impurity EZT-G and degradation impurity EZT-C. The chromatographic conditions can meet the control requirements of related substances in ezetimibe and atorvastatin calcium compound preparations.
[0118] Table 17 Analysis results of each substance peak in the mixed solution
[0119]
[0120] Example 3
[0121] ① Mixed solution spiked with high-risk impurities: Use 60% DMF (containing 0.2% acetic acid) as diluent to prepare a mixed solution spiked with raw materials containing major degradation impurities and high-risk process impurities that may interfere with detection (containing atorvastatin impurities IV / VI / I / K / M / N / O, ezetimibe impurities A / B / C / E / F / G impurities each about 0.005 mg / ml, atorvastatin calcium about 1 mg / ml, and ezetimibe about 0.5 mg / ml).
[0122] ② ATV process impurity mixed solution: Use 60% DMF (containing 0.2% acetic acid) as a diluent to prepare a mixed solution of atorvastatin calcium process impurities. (Contains about 0.0125 mg / ml of each of Atova impurities Ⅰ / Ⅱ / Ⅲ / Ⅴ / Ⅶ / Ⅷ)
[0123] ③ EZT main process impurity mixed solution: Use 60% DMF (containing 0.2% acetic acid) as a diluent to prepare a mixed solution of ezetimibe process impurities. (Contains ezetimibe impurities E / F / H / G, each about 0.005 mg / ml)
[0124] ④ EZT isomer impurity mixed solution: Use 60% DMF (containing 0.2% acetic acid) as a diluent to prepare a mixed solution of ezetimibe process impurities. (Contains about 0.005 mg / ml of each of ezetimibe SSS / RRR / SSR / RRS / RSR isomer impurities)
[0125] ⑤ Location solution of ATV-J / L, the unstable degradation impurity of ATV: Due to the extremely poor stability of ATV-J and ATV-L, location solutions were prepared separately for these two impurities and sampled for judgment in time. 60% DMF (containing 0.2% acetic acid) was used as a diluent to prepare solutions containing about 0.125 mg / ml of ATV-J and ATV-L and a mixed solution of the two components (containing about 0.0625 mg / ml of ATV-J and ATV-L).
[0126] The chromatographic conditions were the same as in Example 2.
[0127] The results of the investigation are shown in Table 18 and Fig. 9 shown. Fig. 9 In the figure, AE are the chromatograms of test solution ①-⑤ respectively.
[0128] ① For the mixed solution spiked with high-risk impurities: baseline separation can be achieved between the main peak of ATV and ATV-I, and between the main peak of EZT and ATV-N, and the separation degree can be higher than 1.5; among the degradation impurities, only ATV-IV and ATV-K1 are difficult to separate, but they can be judged and attributed through RRT, and there is no attribution and control risk; impurity EZT-G is difficult to separate from impurity EZT-C, and the isomeric impurity EZT-SSS / RRR is also insufficiently separated from impurity ATV-I, but impurity EZT-G and isomeric impurity EZT-SSS / RRR are both process impurities, and do not increase during the preparation process and stability process, so they are acceptable.
[0129] ②ATV-J and ATV-L elute after EZT-C (and before ATV-IV), and the separation degree between the two impurities and the front and rear peaks meets the requirements.
[0130] ③ For other process impurities: EZT-B overlaps with ATV-Ⅰ(1), ATV-Ⅱ and ATV-Ⅷ overlap into the main peak of ATV, and EZT-RRS / SSR / RSR isomers also overlap into the main peak of EZT. They are all process impurities, and the preparation process and stability do not increase, which are acceptable.
[0131] Based on the above analysis, for the known process impurities and degradation impurities of ezetimibe atorvastatin calcium compound preparation, the degradation impurities and the two main peaks can be separated, and the separation between the main degradation impurities and between the process impurities and the degradation impurities are also acceptable. The method provided in this embodiment can meet the requirements of the impurity control objectives and control strategies of ezetimibe atorvastatin calcium compound preparation, and is suitable for the determination of related substances of ezetimibe atorvastatin calcium compound preparation.
[0132] Table 18 Summary of the peaks of active ingredients and related substances
[0133]
[0134]
Claims
1. A method for detecting related substances in an ezetimibe and atorvastatin calcium compound preparation, characterized in that: A pentafluorophenyl chromatographic column was used with ammonium acetate buffer at pH 4.8-5.2 as mobile phase A, acetonitrile as mobile phase B, and methanol as mobile phase C for gradient elution to detect related substances in ezetimibe and atorvastatin calcium compound preparations.
2. The detection method according to claim 1, characterized in that: The concentration of ammonium acetate in the mobile phase A is 3.8-4.0 g / L, and the pH is adjusted with glacial acetic acid.
3. The detection method according to claim 2, characterized in that: The concentration of ammonium acetate in the mobile phase A was 3.9 g / L, and the pH was adjusted to 5.0 with glacial acetic acid.
4. The detection method according to claim 1, characterized in that: The elution procedure is: 。 5. The detection method according to claim 1, characterized in that: The elution procedure is 。 6. The detection method according to any one of claims 1 to 4, characterized in that: The detection wavelength is 245~250nm.
7. The detection method according to claim 6, characterized in that: The detection wavelength is 248 nm.
8. The detection method according to claim 6, characterized in that: The column temperature is 25-35°C; the flow rate is 1-2 ml / min.
9. The detection method according to claim 8, characterized in that: The column temperature was 30°C and the flow rate was 1.5 ml / min.
